Postery
Výber aktuálne prezentovaných posterov k problematike SM na medzinárodných kongresoch.
EAN 2023
dokument
1.7.2023
Real world data on natalizumab (Biogen) SC and IV preliminary analysis
3 videnia
Pozrieť 
dokument
1.7.2023
Non inferiority efficacy analysis of natalizumab subcutaneous versus intra venous administration
1 videnie
Pozrieť
dokument
1.7.2023
TYSABRI Observational Program: Long term Safety and Effectiveness in Relapsing Remitting Multiple Sclerosis over 15 Years
2 videnia
Pozrieť
ECTRIMS 2022
dokument
26.6.2024
StratifyJCV™ Serum Anti JCV Antibody Assay for Natalizumab Patients: Unilabs Global Cohort Data Descriptive Analysis and Unilabs Customer Satisfaction Survey Results
1 videnie
Pozrieť
dokument
28.10.2022
SISTER–Subcutaneous: Non-interventional, observational, prospective, German multicenter, open label study over 12 months for Tysabri Patient Preference Experience from Real World –Preliminary results of the 1stinterim analysis
4 videnia
Pozrieť
dokument
28.10.2022
Natalizumab-treated RRMS Patients with Prior DMT Use Report Better Outcomes, Treatment Satisfaction, and Unique Benefits than Similar Patients Treated with Ocrelizumab
3 videnia
Pozrieť
dokument
28.10.2022
Exploratory Magnetic Resonance Imaging Endpoints from NOVA: A Randomised Controlled Study of the Efficacy of 6-week Dosing of Natalizumab vs Continued 4-week Treatment for Multiple Sclerosis
1 videnie
Pozrieť
dokument
28.10.2022
Clinical Effectiveness and Safety of Dimethyl fumarate for Patients Treated at least 6 Years in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5)
1 videnie
Pozrieť
dokument
28.10.2022
Reconstitution of Lymphocytes following discontinuation of Dimethyl fumarate (DMF) due to lymphopenia in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5)
3 videnia
Pozrieť
